DePuy Announces U.S. Settlement Agreement to Compensate ASR™ Hip System Patients Who Had Surgery to Replace Their ASR Hip

   DePuy Announces U.S. Settlement Agreement to Compensate ASR™ Hip System
              Patients Who Had Surgery to Replace Their ASR Hip

PR Newswire

WARSAW, Ind., Nov. 19, 2013

WARSAW, Ind., Nov. 19, 2013 /PRNewswire-USNewswire/ --DePuy Orthopaedics,
Inc. (DePuy) and the Court-appointed committee of lawyers representing ASR™
Hip System plaintiffs today announced a settlement agreement to compensate
eligible ASR patients in the United States who had surgery to replace their
ASR hip, known as revision surgery, as of August 31, 2013.

"We are committed to the well-being of ASR patients, as demonstrated by the
voluntary recall and the program providing support for recall-related care,"
said Andrew Ekdahl, Worldwide President, DePuy Synthes Joint Reconstruction.
"The U.S. settlement program provides compensation for eligible patients
without the delay and uncertainty of protracted litigation. DePuy remains
committed to our purpose of advancing innovative treatment options to serve
those who need joint replacement surgery."

The U.S. settlement is valued at approximately $2.5 billion, based on an
estimate of 8,000 patients participating in the program. The amount of the
settlement program has been included as part of previously accrued amounts,
and no additional charge to the company's earnings is being recorded in
connection with this settlement. Any remaining related established product
liability reserve is based on currently available information and changes to
the reserve may be required in the future as additional information becomes
available. The majority of the payments related to this settlement are
projected to occur during 2014 from currently available cash.

U.S. Settlement Program

For U.S. ASR Patients Who Had Surgery to Remove Their ASR Hip As of August 31,
2013

The U.S. settlement program is available for U.S. ASR patients who had
revision surgery for reasons related to the recall as of August 31, 2013.
Patients eligible for this program can speak with their lawyer, if they have
one, or contact the U.S. settlement program claims processor at
www.USASRHipSettlement.com or (877) 391-3169. ASR patients do not need a
lawyer to participate in the program.

For U.S. ASR Patients Who Have Surgery to Remove Their ASR Hip After August
31, 2013

For U.S. patients who have revision surgery after August 31, 2013, the
existing Broadspire program providing support for recall-related care is
available. U.S. patients are encouraged to call 1-888-627-2677 for more
information.

For more information about the U.S. settlement program, please visit
www.ASRHipInfo.com.

Status of Litigation

Judge David Katz of the U.S. District Court of the Northern District of Ohio
is presiding over the federal multidistrict litigation. The consolidated
state litigations are presided over by: Judge Brian Martinotti of the Superior
Court of New Jersey, Bergen County; Judge Deborah Mary Dooling of the Circuit
Court of Cook County, Illinois; and Judge Richard Kramer of the San Francisco
County Superior Court, California. The settlement agreement was presented to
these judges and Maryland State Court Judge, the Honorable Crystal Dixon
Mittelstaedt, at a court hearing today.

The settlement agreement will help bring to a close significant ASR litigation
activity in the U.S. However, some lawsuits in the U.S. will remain. DePuy
will continue to defend against remaining claims and believes its actions
related to the ASR Hip System have been appropriate and responsible.

Recall Background

In August 2010, DePuy issued a voluntary recall of the ASR Hip System after
receiving new information from the UK National Joint Registry as part of the
company's ongoing surveillance of post-market data concerning the ASR Hip
System, which showed a revision rate that was not in line with data previously
reported in that registry. The product continues to perform well in some
patients. Since the recall decision was made, DePuy has worked to provide
patients and surgeons with the information and support they need, including
the global program providing support for recall-related care, which has thus
far resulted in thousands of payments to patients.

DePuy Orthopaedics, Inc. is part of DePuy Synthes Companies of Johnson &
Johnson.

(This release contains "forward-looking statements" as defined in the Private
Securities Litigation Reform Act of 1995. The reader is cautioned not to rely
on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could vary
materially from the expectations and projections of DePuy Orthopaedics, Inc.
and Johnson & Johnson. Risks and uncertainties include, but are not limited
to, general industry conditions and competition; economic factors, such as
interest rate and currency exchange rate fluctuations; technological advances,
new products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approvals; challenges to
patents; significant adverse litigation or government action; impact of
business combinations; financial distress and bankruptcies experienced by
significant customers and suppliers; changes to governmental laws and
regulations and domestic and foreign health care reforms; trends toward health
care cost containment; increased scrutiny of the health care industry by
government agencies; changes in behavior and spending patterns of purchasers
of health care products and services; financial instability of international
economies and sovereign risk; disruptions due to natural disasters;
manufacturing difficulties or delays; complex global supply chains with
increasing regulatory requirements; and product efficacy or safety concerns
resulting in product recalls or regulatory action. A further list and
description of these risks, uncertainties and other factors can be found in
Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal
year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent
filings, are available online at www.sec.gov, www.investor.jnj.com or on
request from Johnson & Johnson. Neither DePuy Orthopaedics, Inc. nor Johnson
& Johnson undertakes to update any forward-looking statements as a result of
new information or future events or developments.)

Visit www.ASRHipInfo.com for more information.

SOURCE DePuy Orthopaedics, Inc.
 
Press spacebar to pause and continue. Press esc to stop.